Adjuvant Therapies and Markers of Post-Surgical Minimal Residual Disease II: Adjuvant Therapies of the Various Primary Tumors

478 Pages·1979·8.645 MB·English

by  J. Lemerle, M. F. Tournade, C. Patte (auth.), Professor Gianni Bonadonna, Professor Georges Mathé, Professor Sydney E. Salmon (eds.)

Recent Results 68
in Cancer Research
Fortschritte der Krebsforschung
Progres dans Ies recherches sur Ie cancer
Edited by
V. G. AUfrey, New York . M. Allgower, Basel
I. Berenblum, Rehovoth . F. Bergel, Jersey
1. Bernard, Paris . W. Bernhard, Villejuif
N. N. Blokhin, Moskva . H. E. Bock, Tubingen
W. Braun, New Brunswick . P. Bucalossi, Milano
A. V. Chaklin, Moskva . M. Chorazy, Gliwice
G.1. Cunningham, Richmond . G. Della Porta, Milano
P. Denoix, Villejuif . R. Dulbecco, La lolla
~ Eagle, New York . R. Eker, Oslo
R. A. Good, New York . P. Grabar, Paris
R. l. C. Harris, Salisbury . E. Hecker, Heidelberg
R. Herbeuval, Vandoeuvre . J. Higginson, Lyon
W. C. Hueper, Fort Myers . H. Isliker, Lausanne
1. Kieler, Kobenhavn . W. H. Kirsten, Chicago
G. Klein, Stockholm . H. Koprowski, Philadelphia
L. G. Koss, New York· G. Martz, Zurich
G. Mathe, Villejuif . O. Muhlbock, Amsterdam
W. Nakahara, Tokyo· L. l. Old, New York
V. R. Potter, Madison . A. B. Sabin, Charleston, S.c.
L. Sachs, Rehovoth . E. A. Saxen, Helsinki
C. G. Schmidt, Essen . S. Spiegelman, New York
W. Szybalski, Madison . H. Tagnon, Bruxelles
R. M. Taylor, Toronto . A. Tissieres, Geneve
E. Uehlinger, Zurich . R. W. Wissler, Chicago
Editor in Chief: P. Rentchnick, Geneve
Chemotherapy
!
Infiltration Metastasis
Adjuvant Therapies and Markers
of Post-Surgical
Minimal Residual Disease II
Adjuvant Therapies
of the Various Primary Tumors
Edited by
G. Bonadonna G. Mathe S. E. Salmon
With 181 Figures and 218 Tables
Springer-Verlag
Berlin Heidelberg New York 1979
1978 Annual Plenary Meeting of the European Organization for
Research on Treatment of Cancer, Paris, June 1978
Professor Gianni Bonadonna
Istituto Nazionale dei Tumori,
Via Venezian 1
1-20133 Milano
Professor Georges Mathe
Institut de Cancerologie et d'lmmunogenetique
H6pital Paul-Brousse, 14-16, Avenue Paul-Vaillant-Couturier
F-94800 Villejuif
Professor Sydney E. Salmon
University of Arizona Cancer Center
1501 North Campbell Ave.
Tucson, Arizona 85724/USA
Sponsored by the Swiss League against Cancer
ISBN-13: 978-3-642-81334-4 e-ISBN-13: 978-3-642-81332-0
DOl: 10.1007/978-3-642-81332-0
Library of Congress Cataloging in Publication Data. European Organization for
Research on Treatment of Cancer. Adjuvant therapies and markers of post-surgical
minimal residual disease I & II. (Recent results in cancer research; 67-68 "1978
annual plenary meeting of the European Organization for Research on Treatment
of Cancer, Paris, June 1978." "Sponsored by the Swiss League against Cancer."
Bibliography: p. Includes index. I. Cancer-Congresses. 2. Cancer-Surgery-Congresses.
3. Tumor proteins-Congresses. 4. Therapeutics-Congresses. 1. Bonadonna. G .. 1934 -
n. Mathe, Georges, 1922 - III. Salmon. Sydney E. - IV. Schweizerische Nationalliga
fiir Krebsbekiimpfung und Krebsforschung. - V. Title. VI. Series. RC261.R35
no.67-68 [RC270.8) 616.9'94'008s 79-9998 [616.9'94'()6j
This work is subject to copyright. All rights are reserved, whether the wholc or
part of the material is concerned, specifically those of translation, reprinting, re-use
of illustrations, broadcasting, reproduction by photocopying machine or similar means.
and storage in data banks. Under § 54 of the German Copyright Law where copies
are for other than private use, a fee is payable to the publisher, the amount of thc
fee to be determined by agreement with the publisher.
© Springer-Verlag Berlin Heidelberg 1979
Softcover reprint ofthe hardcover 1s t edition 1979
The use of registered names, trademarks. etc. in the publication does not imply.
even in the absence of a specific statement, that such names are exempt from the
relevant protective laws and regulations and therefore free for general use.
Typesetting: Carl Ritter & Co.lWiesbaden
2125/3140-543210
Contents
B. Wilms' Tumor and Sarcomas
J. Lemerle, M. F. Tournade, and C. Patte: Wilms' Tumor: Assessment and Treatment of
Residual Disease ............................................................. .
K. Breur and E. van der Schueren: Adjuvant Therapy in the Management of Osteosarcoma:
Need for Critical Reassessment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
E. P. Cortes, J. F. Holland, and O. Glidewell: Adjuvant Therapy of Operable Primary Osteo-
sarcoma-Cancer and Leukemia Group B Experience ............................... 16
F. Fossati-Bellani, M. Gasparini, and G. Bonadonna: Adriamycin in the Adjuvant Treatment
of Operable Osteosarcoma .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
C. Jasmin: Randomized Trial of Adjuvant Chemotherapy in Osteogenic Osteosarcoma: Com
parison of Altering Sequential Administrations of High Doses of Adriamycin, Methotrexate,
and Cyclophosphamide with a 6-Month Administration of High-Dose Adriamycin Followed by
a Low-Dose Semicontinuous Chemotherapy. EORTC-Osteosarcoma Working Party
Group........................................................................ 28
W. Wilmanns, H. Sauer, and A. Schalhorn: Biochemistry of the Citrovorum Factor Rescue
Effect in Normal Bone Marrow Cells After High-Dose Methotrexate Treatment: Implications
for Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
H. Strander, U. Adamson, T. Aparisi, L. A. Brostrom, K. Cantell, S. Einhorn, K. Hall,
S. Ingimarsson, U. Nilsonne, and G. Soderberg: Adjuvant Interferon Treatment of Human
Osteosarcoma ................................................................. 40
M. Gasparini, F. Fossati-Bellani, and G. Bonadonna: Current Results With a Combined Treat-
ment Approach to Localized Ewing's Sarcoma .................................... 45
B. P. Le Mevel et al.: EORTC/GTO Adjuvant Chemotherapy Program for Primary Ewing's
Sarcoma: Results at 5 Years. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
V. H. C. Bramwell, P. A. Vofite, S. A. Rosenberg, and H. M. Pinedo: Adjuvant Treatment of
Soft Tissue Sarcoma in Children and Adults ...................................... 60
C. Breast Carcinoma
K. E. Halnan: Place and Role of Radiotherapy After Surgery for Breast Cancer. . . . . . . 75
A. Rossi, P. Valagussa, and G. Bonadonna: Combined Modality Management of Operable
Breast Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
VI Contents
S. E. Salmon, A. Wendt, S. E. Jones, R. Jackson, G. Giordano, R. Miller, R. Heusinkveld, and
T. E. Moon: Treatment of Early Breast Cancer With Adriamycin-Cyclophosphamide With or
Without Radiation Therapy: Initial Results of a Brief and Effective Adjuvant Program. 98
B. Serrou, H. Sancho-Garnier, P. Cappelaere, R. Plagne, R. Metz, M. Schneider, P. Chollet,
M. N amer, H. Pujol, J. Gary-Bobo, G. Meyer, and G. Mathe: Results of a Randomized Trial of
Prophylactic Chemotherapy in TcT4 Breast Cancer Patients Previously Treated by Radio-
therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
G. A. Edelstyn, I. S. Bates, D. Brinkley, K. D. MacRae, H. Spittle, and T. Wheeler: Four Drug
Combination Cytotoxic Chemotherapy Following Surgery for Breast Cancer .......... 109
C. Schaake, E. Engelsman, and E. Hamersma: Pilot Study on Adjuvant Chemotherapy and
Hormonal Therapy for Irradiated Inoperable Breast Cancer. . . . . . . . . . . . . . . . . . . . . . . . . 113
J. W. Meakin, W. E. C. Alit, F. A. Beale, R. S. Bush, R. M. Clark, P. J. Fitzpatrick, N. V.
Hawkins, R. D. T. Jenkin, J. F. Pringle, J. G. Reid, and W. D. Rider: Ovarian Irradiation and
Prednisone Following Surgery and Radiotherapy for Carcinoma of the Breast. . . . . . . . . 118
A. V. Buzdar, J. U. Gutterman, G. R. Blumenschein, Ch. K. Tashima, G. N. Hortobagyi,
H.-Y. Yap, E. M. Hersh, and E. A. Gehan: Adjuvant Therapy of Stage II, III Breast
Cancer...... ...................... .. .......... ..... ...... ............. ....... 123
F. Lacour, G. Delage, A. Spira, E. Nahon-Merlin, J. Lacour, A. M. Michelson, and S. Bayet:
Randomized Trial With Poly A - Poly U as Adjuvant Therapy Complementing Surgery in
Patients With Breast Cancer: In vitro Study of Cellular Immunity. . . . . . . . . . . . . . . . . . . 129
E. J. W. Stephens, H. F. Wood, and B. Mason: Levamisole: As Adjuvant to Cyclic Chemo-
therapy in Breast Cancer ...................................................... 139
D. Ovary, Uterus and Testis Cancer
C. Mangioni, G. Bolis, M. D. Incalci, P. Molteni, and L. Morasca: Laparoscopy and Peritoneal
Cytology as Markers in the Follow-Up of Ovarian Epithelial Tumors. . . . . . . . . . . . . . . . 146
D. Chassagne and J. P. Wolff: Radiotherapy in Ovarian Cancer for Post-Surgical Minimal
Residual Disease .............................................................. 152
J. H. Edmonson, T. R. Fleming, D. G. Decker, E. O. Jorgensen, G. D. Malkasian, J. A. Jeffe
ries, L. K. Kvols, and M. J. Webb: Chemotherapeutic Sensitivity of Minimal Residual Disease
Following Surgical Excision of Ovarian Carcinoma ................................ 157
D. S. Alberts, S. E. Salmon, and T. E. Moon: Chemoimmunotherapy for Advanced Ovarian
Carcinoma With Adriamycin-Cyclophosphamide ± BCG: Early Report of a Southwest
Oncology Group Study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
M. E. Crowther, L. Levin, T. A. Poulton, M. J. Saffrey, O. M. Curling, and C. N. Hudson:
Active Specific Immunotherapy in Ovarian Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
T. Taguchi: Clinical Studies on PSK: Combination Therapy ofPSK With Radiation in Cancer
of the Uterine Cervix .......................................................... 174
Contents VII
H. F. Hope-Stone: Irradiation as Adjuvant Therapy in the Management of Testicular
Tumors....................................................................... 178
E. Pommatau, C. Ardiet, M. Brunat-Mentigny, J. L. Chassard, and M. Mayer: Adjuvant
Chemotherapy in Embryonal Carcinoma of the Testis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 186
F. M. Muggia and E. M. Jacobs: Adjuvant Chemotherapy of Testicular Carcinoma: Need for
Evaluation of Curative Strategies ................................................ 192
M. Hartmann and F. Korner: Results of Cytostatic Therapy of Metastasizing Testicular
Tumors....................................................................... 201
E. Digestive Tract Tumors
J. C. Goffin and D. Machin: Treatment of Patients With Gastric Cancer by Surgery, Radio
therapy, and Chemotherapy: Preliminary Results of an EORTC Randomized Study ... 208
G. R. Giles and J. O. Lawton: Chemotherapy for Known Residual Disease After Resection of
Gastric and Colorectal Cancer .................................................. 212
J. M. Gilbert, P. Cassell, H. Ellis, Ch. Wastell, J. Hermon-Taylor, and K. Hellman: Adjuvant
Treatment With Razoxane (ICRF 159) Following Resection of Cancer of the Stomach. 217
T. B. Grage, G. J. Hill, G. N. Cornell, R. W. Frelick, and S. E. Moss: Adjuvant Chemotherapy
in Large-Bowel Cancer: Demonstration of Effectiveness of Single Agent Chemotherapy in a
Prospectively Controlled, Randomized Trial ....................................... 222
P. V. Woolley, G. A. Higgins, and Ph. S. Schein: Ongoing Trials in the Surgical Adjuvant
Management of Colorectal Cancer .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
T. Taguchi: Clinical Studies on PSK: Combination Therapy ofPSK With Surgery and Chemo-
therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236
F. Bronchus Carcinoma
J. Stjernsward: Role of Radiotherapy as an Adjuvant Therapy in Operable Bronchus Carcino-
ma........................................................................... 241
L. Israel, A. Depierre, and R. Sylvester: Influence of Postoperative Radiotherapy on Local
Recurrence and Survival of Bronchial Epidermoid Carcinoma With Regard to Nodal Status:
Preliminary Results of the EORTC Protocol 08741 ................................ 242
L. Israel, A. Depierre, and R. Sylvester: Preliminary Trends of the EORTC Study Comparing
Postoperative Chemotherapy, Immunotherapy, Chemoimmunotherapy or Abstention in
Squamous Cell Bronchial Carcinoma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 244
K. Karrer: Adjuvant Chemotherapy of Post-Surgical Minimal Residual Bronchial Carcino-
mas.......................................................................... 246
P. Pouillart, T. Palangie, P. Huguenin, P. Morin, H. Gautier, A. Baron, andG. Mathe: Attempt
at Immunotherapy With Living BCG in Patients With Bronchus Carcinoma .......... 260
VIII Contents
W. K. Amery, J. Cosemans, H. C. Gooszen, E. Lopes Cardozo, A. Louwagie, J. Starn,
J. Swierenga, R. G. Vanderschueren, and R. W. Veldhuizen: Adjuvant Therapy With Levami-
sole in Resectable Lung Cancer ................................................. 268
T. H. M. Stewart, A. C. Hollinshead, J. E. Harris, S. Raman, R. Belanger, A. Crepeau,
A. F. Crook, W. E. Hirte, D. Hooper, D. J. Klaasen, E. F. Rapp, and H. J. Sachs: Specific
Active Imunochemotherapy in Lung Cancer: A Survival Study. . . . . . . . . . . . . . . . . . . . . . 278
M. F. McKneally, C. Maver, S. Kellar, and L. Lininger: Patterns of Recurrence After Regional
BCG Immunotherapy of Bronchial Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 286
P. B. lies, D. F. Shore, M. J. S. Langmann, R. W. Baldwin: Intrapleural BCG in Operable
Lung Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 292
G. Head and Neck Tumors
S. G. Taylor, G. A. Sisson, and D. E. By tell: Adjuvant Chemoimmunotherapy of Head and
Neck Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297
H. Szpirglas, Cl. Chastang, and J. C. Bertrand: Adjuvant Treatment of Tongue and Floor of the
Mouth Cancers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 309
J. L. Amiel, H. Sancho-Garnier, C. Vandenbrouck, F. Eschwege, J. P. Droz, G. Schwaab,
P. Wibault, M. Stromboni, and A. Rey: First Results of a Randomized Trial on Immunother-
apy of Head and Neck Tumors................................................. 318
H. J. Wanebo, E. Y. Hilal, E. W. Strong, C. M. Pinsky, V. Mike, and H. F. Oettgen: Adjuvant
Trial of Levamisole in Patients With Squamous Cancer of the Head and Neck: A Preliminary
Report ....................................................................... 324
H. Urological Tumors
B. Richards, A. Akdas, P. Corbett, R. W. Glashan, M. R. G. Robinson, and P. A. Smith:
Adjuvant Chemotherapy Following Radical Radiotherapy in T3 Bladder Carcinoma ... 334
C. Schulman, R. Sylvester, M. Robinson, P. Smith, A. Lachand, L. Denis, M. Pavone-Macalu-
so, M. De Pauw, and M. Staquet: Adjuvant Therapy of T1 Bladder Carcinoma: Preliminary
Results of an EORTC Randomized Study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 338
l. Melanoma
C. Jaquillat, P. Banzet, J. Civatte, P. Puissant, F. Cottenot, L. Israel, S. Belaich, Cl. Chastang,
and J. Maral: Adjuvant Chemotherapy or Chemoimmunotherapy in the Management of
Primary Malignant Melanoma of Level III, IV, or V . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 346
J. U. Gutterman, S. P. Richman, C. M. McBride, M. A. Burgess, S. L. Bartold, A. Kennedy,
E. A. Gehan, G. Mavligit, and E. M. Hersh: Immunotherapy for Recurrent Malignant Melano
ma: Efficacy of BCG in Prolonging the Postoperative Disease-Free Interval and
Survival ...................................................................... 359
Contents IX
B. Serrou, H. Pujol, J. Domas, and L. Gaud: Results of a Nonrandomized Trial in Malignant
Melanoma Patients (Clark's Stages III-V) Treated by Post-Surgical Chemoimmuno-
therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 363
H. H. Peter,K. E. M. Deutschmann,J. Deinhardt,andH. Deicher: Value of Adjuvant Therapy
With Bacille Calmette Guerin (BCG) or Dimethyl Triazeno Imidazole Carboximide (DTIC) in
the Control of Minimal Residual Disease in Stage II Melanoma ., . . . . . . . . . . . . . . . . . . . 367
U. Veronesi and G. Beretta: Controlled Study for Prolonged Chemotherapy, Immunotherapy,
and Chemotherapy Plus Immunotherapy as an Adjuvant to Surgery in Malignant Melanoma
(Trial 6): Preliminary Report. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375
S. D. Kaufman,A. B. Cosimi, W. C. Wood,andR. W. Carey: Adjuvant Therapy in Malignant
Melanoma: A Trial of Immunotherapy, Chemotherapy, and Combined Treatment ..... 380
A. H. G. Paterson, D. Willans, L. M. Jerry, and T. A. McPherson: Malignant Melanoma
(Stage I): A Clinical Trial of Adjuvant BCG Immunotherapy ....................... 387
J. Neurological Tumors
S. Monfardini, C. Brambilla, C. L. Solero, A. Vaghi, P. Valagussa, G. Morello, and G. Bona
donna: Adjuvant Chemotherapy With Nitrosourea Compounds Following Surgery Plus Radio
therapy in Glioblastoma Multiforme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 393
P. Pouillart, T. Palangie, M. Poisson, A. Buge, P. Huguenin, P. Morin, and H. Gautier: Treat-
ment of Adult Malignant Gliomas ............................................... 399
J. Hildebrand: Adjuvant Chemotherapy in Malignant Brain Gliomas ................. 408
H. J. G. Bloom: Adjuvant Therapy for Residual Disease in Children With Medulloblasto-
ma........................................................................... 412
J. M. Zucker and E. Margulis: Radiochemotherapy of Postoperative Minimal Residual Disease
in Neuroblastoma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 423
K. Tumors Not Yet Submitted to Adjuvant Chemotherapy and Immunotherapy Trials
F. M. Muggia and M. Rozencweig: Adjuvant Systemic Therapy of Cancer: Rationale for
Future Trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 431
G. Mathe, M. Hayat, J. L. Misset, M. Bayssas, J. Gouveia, F. De Vassal, M. Delgado,
M. A. Gil, P. Ribaud, D. Machover, V. Slioussartchouk, and D. Dantchev: Some New Chemo
therapeutic Agents and Combinations Possibly Available for New Adjuvant Therapies of
Minimal Disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 439
G. Mathe, I. Florentin, J. I. Schulz, M. Bruley-Rosset, and N. Kiger: Third Generation of
Systemic Adjuvants of Immunity: Experimental Basis for Adjuvant Combinations ..... 449
A. Goldin, A. Nicolin, and E. Bonmassar: Interrelationship Between Chemotherapy and
Immunotherapy in the Treatment of Disseminated Disease. . . . . . . . . . . . . . . . . . . . . . . . . . 458
L. Lajtha: Concluding Remarks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 465
List of Participants see Volume 67, pp. XII-XVIII
Contents of Volume 67
Adjuvant Therapies and Markers of Post-Surgical Mininal Residual Disease I
P. Denoix and G. Mathe: Introduction
I. Incidence, Kinetics and Markers of Post-Surgical Minimal Residual Disease
S. E. Salmon: Kinetics of Minimal Residual Disease
X. Y. Bertagna, W. E. Nicholson, K. Tanaka, Ch. D. Mount, G. D. Sorenson, O. S. Pettengill, and
D. N. Orth: Ectopic Production of ACTH, Lipotropin, and ,8-Endorphin by Human Cancer Cells.
Structurally Related Tumor Markers
R. E. Myers, D. J. A. Sutherland,J. W. Meakin, D. G. Malkin,J. A. Kellen, and A. Malkin: Prognos
tic Value of Postoperative Blood Levels of Carcinoembryonic Antigen (CEA) in Breast
Cancer
D. Buffe and C. Rimbaut: a-Fetoprotein (aFP) as a Marker for Hepatoma and Yolk Sac
Tumors
J. C. Hendrick, P. F. Zangerle, and P. Franchimont: Casein and Breast Cancer
A. G. Foti, J. F. Cooper, and H. Herschman: Prostatic Acid Phosphatase and Prostatic Cancer
U. Ganzinger and K. Moser: Sialyl Transferase Activity: A Serum Enzyme Marker in the Follow-Up
of Cancer Patients
A. M. Roch, G. A. Quash, J. P. Ripoll, and S. Saez: Evidence for Natural Antibodies (IgG) to
Polyamines in Human Sera
C. Rosenfeld, C. Jasmin, G. Mathe, and M. Inbar: Dynamic and Composition of Cellular Membranes
and Serum Lipids in Malignant Disorders
R. Maurus and J. Otten: Biologic Markers in Neuroblastoma
R. W. Baldwin, K. H5ffken, and R. A. Robins: Immune Complexes in Breast Carcinoma
A. Fassas and M. Bruley-Rosset: Serum Leukocyte Inhibitory Factor in Cancer Patients (Serum
LIF)
D. E. H. Tee: Clinical Evaluation of the Modified Markari Skin Test in Minimal Residual Malignant
Disease
E. H. Cooper: Multiparametric Markers in the Monitoring of Cancer